Spontaneous abrogation of the G(2) DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients by Ceccaldi, R. et al.
Research article
184	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 121	 	 	 Number 1	 	 	 January 2011
Spontaneous abrogation of the G2 DNA 
damage checkpoint has clinical benefits  
but promotes leukemogenesis  
in Fanconi anemia patients
Raphael Ceccaldi,1,2,3 Delphine Briot,1,2,3 Jérôme Larghero,4 Nadia Vasquez,1,2,3  
Catherine Dubois d’Enghien,5 Delphine Chamousset,1,2,3 Maria-Elena Noguera,1,2,3  
Quinten Waisfisz,6 Olivier Hermine,7 Corinne Pondarre,8 Thierry Leblanc,9 Eliane Gluckman,10,11 
Hans Joenje,6 Dominique Stoppa-Lyonnet,5 Gérard Socié,11 and Jean Soulier1,2,3
1INSERM U944 and 2Hematology Laboratory Assistance Publique – Hôpitaux de Paris (APHP), Saint-Louis Hospital, Paris, France.  
3Institute of Hematology (IUH), University Paris Diderot, Paris, France. 4Laboratory of Cellular Biology, Saint-Louis Hospital, Paris, France.  
5Oncogenetic Laboratory, Curie Institute, Paris, France. 6Vrije University, Amsterdam, The Netherlands. 7Hematology Department, Necker Hospital,  
Paris, France. 8Institut d’Hématologie et d’Oncologie-Pédiatrique, Hospices civils de Lyon, Lyon, France. 9Department of Pediatric Hematology,  
Saint-Louis and Robert Debré Hospitals, Paris, France. 10Eurocord and 11Department of Bone Marrow Transplant, Saint-Louis Hospital, Paris, France.
DNA	damage	checkpoints	in	the	cell	cycle	may	be	important	barriers	against	cancer	progression	in	human	
cells.	Fanconi	anemia	(FA)	is	an	inherited	DNA	instability	disorder	that	is	associated	with	bone	marrow	fail-
ure	and	a	strong	predisposition	to	cancer.	Although	FA	cells	experience	constitutive	chromosomal	breaks,	cell	
cycle	arrest	at	the	G2	DNA	damage	checkpoint,	and	an	excess	of	cell	death,	some	patients	do	become	clinically	
stable,	and	the	mechanisms	underlying	this,	other	than	spontaneous	reversion	of	the	disease-causing	muta-
tion,	are	not	well	understood.	Here	we	have	defined	a	clonal	phenotype,	termed	attenuation,	in	which	FA	
patients	acquire	an	abrogation	of	the	G2	checkpoint	arrest.	Attenuated	cells	expressed	lower	levels	of	CHK1	
(also	known	as	CHEK1)	and	p53.	The	attenuation	could	be	recapitulated	by	modulating	the	ATR/CHK1	path-
way,	and	CHK1	inhibition	protected	FA	cells	from	cell	death.	FA	patients	who	expressed	the	attenuated	phe-
notype	had	mild	bone	marrow	deficiency	and	reached	adulthood,	but	several	of	them	eventually	developed	
myelodysplasia	or	leukemia.	Better	understanding	of	attenuation	might	help	predict	a	patient’s	clinical	course	
and	guide	choice	of	treatment.	Our	results	also	highlight	the	importance	of	evaluating	the	cellular	DNA	dam-
age	checkpoint	and	repair	pathways	in	cancer	therapies	in	general.
Introduction
Checkpoint pathways are complex biological pathways that 
regulate responses to DNA damage and other cellular events 
(1–3). The typical DNA damage checkpoint response triggers 
cell cycle arrest, allowing time for DNA repair, and impairments 
in checkpoints favor genomic instability and cancer (4). In 
humans, DNA damage checkpoint pathways include the post-
translational activation of the transduction proteins CHK1 
checkpoint homolog (Schizosaccharomyces pombe) (CHK1, also 
known as CHEK1) and CHK2 checkpoint homolog (S. pombe) 
(CHK2) by PI3-like kinase ataxia telangiectasia and Rad3 relat-
ed (ATR) and ataxia telangiectasia mutated (ATM) (4, 5). If 
cells can not repair damage during cell cycle arrest, cell death is 
induced. Recently, DNA damage response pathways have also 
been implicated in cellular responses to oncogenic activation, 
and checkpoint pathways are believed to constitute a first-line 
anticancer barrier (6–8). Therefore, an important step of cancer 
progression is the inactivation of checkpoint pathways. Here we 
studied a series of patients with Fanconi anemia (FA), a genetic 
disease that is characterized by genomic instability, checkpoint 
arrest, and cancer predisposition and identified what we believe 
to be a new cellular phenotype that is associated with clonal 
evolution and leukemogenesis.
FA is an inherited condition that is caused by mutations in 
1 out of the 13 FA-associated genes (9, 10). Products of these 
genes interact in the FANC/BRCA pathway, in which a pivot-
al event is the monoubiquitination of FA, complementation 
group D2 (FANCD2) (11). Affected patients can develop vari-
ous congenital abnormalities, including short stature (12, 13). 
They usually experience bone marrow failure during childhood, 
and they have a considerable predisposition to cancer, especial-
ly myelodysplasia (MDS), acute myeloid leukemia (AML), and 
head and neck cancers (12–16). FA cells are hypersensitive to 
DNA interstrand crosslinking (ICL) agents and harbor high lev-
els of spontaneous and induced chromosome breaks (9, 10, 12, 
13). On exposure to ICL agents, such as mitomycin C (MMC), 
FA cells undergo massive G2 arrest, which is considered a nor-
mal checkpoint response to unresolved DNA damage during 
S phase (17–19). Consequently, FA cells experience slower pro-
gression through the cell cycle, inhibition of growth, increased 
p53 expression, and cell death (20–22). FA cells can undergo 
somatic mosaicism by spontaneous reverse mutation or mitotic 
recombination (23–25). This phenomenon of reversion allows 
genetically corrected cells to be selected to repopulate the bone 
Authorship	note: Raphael Ceccaldi, Nadia Vasquez, Delphine Chamousset, Thierry 
Leblanc, Eliane Gluckman, Gérard Socié, and Jean Soulier are members of the French 
National Reference Center for Constitutional Bone Marrow Failure.
Conflict	of	interest: The authors have declared that no conflict of interest exists.
Citation	for	this	article: J Clin Invest. 2011;121(1):184–194. doi:10.1172/JCI43836.
  Related Commentary, page 27
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 121   Number 1   January 2011 185
marrow. This spontaneous “endogenous gene therapy” has been 
associated with higher blood cell counts and clinical improve-
ment (25, 26) and occasionally with cancer (27).
In this study, we describe a type of clonal evolution in FA 
— attenuation of the G2 checkpoint — which does not correct 
genomic instability but overrides it by promoting cell survival. 
The biological pathways that are involved in cell cycle check-
points, including the ATR-CHK1 axis, were investigated in atten-
uated FA cells. Patients with attenuated cells were clinically stable, 
but some eventually developed leukemia. These data, based on 
a human genetic condition, highlight the complex relationships 
among genomic instability, clonal evolution, cell survival, and 
cancer. The cellular mechanisms and concepts in FA patients 
that we describe have implications for general cancer biology and 
responses to chemotherapy.
Results
A new phenotype in FA patients — attenuation of the G2 checkpoint in 
response to DNA damage. FA cells are characteristically hypersensi-
tive to DNA crosslinking agents. During diagnosis or follow-up 
evaluation of FA patients, we noted patients in whom the FA tests 
on peripheral blood lymphocytes (PBLs) were dissociated. In these 
patients, phytohemagglutinin-stimulated (PHA-stimulated) fresh 
PBLs did not arrest in G2 phase after MMC exposure, although they 
harbored chromosomal breaks and lacked FANCD2 monoubiqui-
tination (Figure 1 and Supplemental Figure 1; supplemental mate-
rial available online with this article; doi:10.1172/JCI43836DS1). 
The abrogation of the G2 checkpoint was previously reported in 
rare (non-FA) cancer cell lines, and it was defined as attenuation 
(28). Based on our observation, we hypothesized that the G2 check-
point can be attenuated in FA cells, prompting us to evaluate this 
phenomenon in a large cohort of FA patients. We defined the atten-
uated phenotype as the combination of (a) a high level of chromo-
somal breaks after MMC exposure in the Fanconi range (“positive 
chromosome breakage test”); (b) a lack of FANCD2 monoubiqui-
tination, characteristic of FA cells with an upstream defect in the 
FA/BRCA pathway (“positive FANCD2 test”); and (c) a paradoxical 
absence or significant decrease in MMC-induced FA cell G2 arrest 
(“negative cell cycle test”). These criteria allowed us to differentiate 
the attenuated phenotype from that of “classical” FA, in which all 3 
tests are positive, and from that of reversion, in which the 3 tests are 
completely or partially normalized (somatic mosaicism).
Attenuation is found in older FA patients and is associated with milder 
bone marrow failure or MDS/leukemia. We evaluated a cohort of 97 
FA patients (group FA-A, n = 80; FA-G, n = 9; FA-D2, n = 7; other, 
n = 1) for the presence of attenuation. This cohort included FA 
patients at Saint-Louis Hospital who underwent a complete analy-
sis of fresh PBLs, particularly in the oldest patients, and excluded 
bone marrow transplantation patients. The 97 patients were clas-
sified as classical FA (i.e., patients with a standard FA phenotype), 
revertant, or attenuated. Sixty-eight out of ninety-seven patients 
had classical FA (70.1%), 12 patients had a revertant phenotype 
(12.4%), and 17 patients had the attenuated phenotype (17.5%). 
Patients with the attenuated phenotype were clearly not revertants, 
because they had a positive chromosome breakage test and lacked 
FANCD2 monoubiquitination in PHA-stimulated PBLs. In addi-
tion, reversion events were not observed after resequencing the 
FANC mutations in the PBLs of the attenuated patients (n = 10), 
whereas 3 revertant cases, tested as controls, harbored a point 
reversion in DNA from their PBLs (data not shown).
We analyzed the distribution of the FA phenotypes by patient age 
(Figure 1E). Notably, whereas reversion and attenuation were rare 
compared with classical FA in young patients, most patients with 
an attenuated or revertant phenotype were over 20 years of age. 
The median blood cell count in attenuated patients approximated 
normal levels (hemoglobin, 12.6 g/l; white blood cells, 3.9 × 109/l, 
neutrophil cells, 1.8 × 109/l, platelets 106 × 109/l), suggesting that 
attenuation, like reversion (26), was associated with a better clini-
cal outcome with respect to bone marrow failure, allowing patients 
to reach adulthood (7 out of the 17 patients with the attenuated 
phenotype did not experience bone marrow failure; Supplemental 
Table 1). Notably, 5 FA patients (aged 16, 20, 26, 36, and 50 years) 
with the attenuated phenotype in PHA-stimulated PBLs developed 
MDS or AML (Supplemental Table 1).
Collectively, these data demonstrate that attenuation is frequent 
in older FA patients and is associated with better clinical outcomes 
but also that it can be found in patients with MDS or leukemia.
The attenuated phenotype is acquired. Next, we determined whether 
the attenuated phenotype was acquired or constitutive. The FANC 
data from the 17 attenuated phenotype patients could not exclude 
in all cases the possibility of hypomorphic mutations (Supplemen-
tal Table 1 and ref. 29). Therefore, we performed FA tests on pri-
mary fibroblasts, as constitutive cells, which we could perform for 
16 out of 17 patients. Two patients experienced intermediate G2 
arrest and mild MMC sensitivity in their fibroblasts, and they were 
excluded from further analysis. In the remaining 14 patients, pri-
mary fibroblasts showed massive MMC-induced G2 arrest, typical 
of FA (Figure 1B and Supplemental Table 1). The patent difference 
between the PBL and fibroblast data demonstrated that attenua-
tion, like reversion, was an acquired, not constitutive, phenotype. 
In addition, conversion from the classical to attenuated FA phe-
notype occurred in 2 patients at distant analyses (at 6- and 3-year 
intervals, respectively; Supplemental Figure 2).
Clonality of attenuated cells. To determine whether attenuation in 
PBLs was related to clonal evolution, we searched for somatic chro-
mosomal abnormalities. Genomic DNA from PBLs of attenuated 
patients was subjected to high-resolution chromosomal profiling 
(array-CGH/SNP). In 8 out of 13 cases, gross chromosomal copy 
number alterations were observed (Figure 2A and Supplemental 
Table 1). Notably, such alterations included several chromosomal 
abnormalities that are common in FA clonal evolution, such as 
gain of chromosome arm 1q or 3q and deletion of 11q.
In a separate approach, we measured clonality by X-linked inac-
tivation analysis (Figure 2B). All 5 patients with the attenuated 
phenotype who could be analyzed, including 3 without detectable 
chromosomal abnormalities, showed skewed allelic expression 
that was consistent with clonal selection. In contrast, nearly all 
healthy controls had a balanced pattern. As expected, the revertant 
patient showed skewed allelic expression. Balanced allelic expres-
sion was observed in 3 out of 6 classical FA patients, consistent 
with polyclonal cells, and interestingly, a skewed expression was 
noted in the 3 others, suggesting that mechanisms other than 
attenuation also lead to clonal restriction in FA.
Collectively, these data are consistent with a model of natural 
selection of the attenuated cells in FA patients.
Downregulation of checkpoint proteins in attenuated FA cells. We 
hypothesized that an acquired defect in the checkpoint pathways 
caused the attenuated phenotype. Expression of the prototypi-
cal DNA damage response proteins CHK1, CHK2, and p53 was 
measured in fresh blood samples from 9 attenuated phenotype 
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patients, 14 classical FA subjects, and 4 healthy samples (Figure 3). 
p53 expression was high in classical FA cells compared with that 
in healthy controls (Figure 3A), suggesting that p53 is induced in 
fresh FA cells in response to endogenous and induced DNA dam-
age, consistent with previous reports of human FA EBV cell lines 
and murine fibroblasts (20–22). Notably, we observed low expres-
sion of CHK1 and p53 in the PHA-stimulated PBLs of 6 out of 9 
attenuated phenotype patients compared with that in classical FA 
Figure 1
Attenuation of G2 arrest — a new phenotype in FA. (A) Cell cycle analysis of PHA-stimulated PBLs from a classical FA patient (FA), an attenuated 
FA patient (ATT), a revertant (REV; somatic mosaic), and a healthy control (Ctrl). The arrow indicates the typical MMC-induced G2 arrest of clas-
sical FA cells, and the asterisk designates the G2 checkpoint abrogation in the attenuated cells; as expected, revertant cells demonstrated no G2 
arrest. (B) Cell cycle analysis of primary fibroblasts (fibro) from the same patients, showing G2 arrest (arrow) and confirming the constitutive FA 
phenotype and dissociation with PBLs in attenuated and revertant patients. Horizontal bars in A and B indicate the G1 and G2 cell cycle phases 
(M1 and M2, respectively). (C) Immunoblot analysis showed that attenuated FA PBLs lacked the large monoubiquitinated 162-kDa isoform of 
FANCD2 (asterisk), like classical FA cells and unlike revertant cells; primary fibroblasts retained the FA phenotype. (D) Attenuated cells still have 
a high number of MMC-induced chromosomal breaks, like classical FA cells and unlike revertant cells (original magnification, ×630). Arrows 
indicate the chromosome breaks. Breaks scoring are shown in Supplemental Figure 1. (E) Classification of the FA patients as having classical, 
revertant, and attenuated PBL phenotypes and ordering by class age: fewer than 5 years (n = 9; 9.5%), 5–9 years (n = 31; 32.6%), 10–14 years 
(n = 15; 15.8%), 15–19 years (n = 11; 11.6%), 20–24 years (n = 10; 10.5%), 25–29 years (n = 9; 9.5%), and more than 30 years (n = 10; 10.5%). 
For the clarity of the figure, 2 patients whose fibroblasts were later found to be intermediate for G2 arrest are not shown (see text). 
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subjects but not in the fibroblasts (Figure 3A and data not shown). 
Moreover, low levels of CHK1 but not CHK2 transcripts were detect-
ed by real-time quantitative PCR (RQ-PCR) in most attenuated 
patients compared with patients with classical FA (Figure 3B). By 
analyzing sequence and copy number of CHK1 and TP53 in low-
expression level patients, no genomic mutation or focused dele-
tion was detected, suggesting other mechanisms of deregulation. 
We therefore investigated epigenetic changes. Whereas we found 
no DNA methylation changes in attenuated cells (Supplemental 
Figure 3A), in silico analysis of CHK1 3′ UTR predicted numer-
ous target sites for 2 microRNAs, namely miR15-a and miR16-1, 
which were previously reported to target CHK1 expression (30); 
interestingly, we found a higher expression of miR15-a, but not 
miR16-1, in attenuated cells compared with that in classical FA 
cells, suggesting a mechanism of CHK1 expression downregula-
tion (Supplemental Figure 3B). In addition, unlike CHK2, which is 
a stable protein, CHK1 is a rather unstable protein due to protea-
some degradation (31). We evaluated CHK1 turnover and found 
an acceleration in the attenuated cells, demonstrating that post-
translational mechanisms could also contribute to the low levels 
of CHK1, which were observed during attenuation (Figure 3C).
Based on these data, the transcriptional and/or posttransla-
tional downregulation of CHK1 expression constituted a putative 
mechanism for attenuation of the G2 checkpoint in FA cells.
Suppression of the ATR/CHK1 checkpoint pathway reproduced the 
attenuated phenotype and protects FA cells from DNA damage-induced 
cell death in short-term culture. We determined whether attenuation 
could be recapitulated by checkpoint inhibition. We used an siRNA 
Figure 2
Clonality of attenuated FA cells. (A) Array-CGH showed clonal chromosomal abnormalities in PHA-stimulated PBLs from an attenuated patient. 
MGG stains confirmed the activated lymphoblast morphology (original magnification, ×400). Arrows indicate copy number abnormalities. 
(B) X-linked–based analysis of clonality; female FA patients who were heterozygous for 1 or more of the 3 SNPs in the X chromosome were iden-
tified by direct sequencing of genomic DNA. Then, allelic X-linked inactivation was evaluated in a semiquantitative manner by sequencing PBL 
cDNA from these patients. The left panel shows balanced expression of the heterozygous MMP1 SNP in a healthy control and a classical FA 
patient, whereas skewed expression was detected in the attenuated and revertant patients (asterisks). The right panel summarizes the X-linked 
clonality data in heterozygous PBLs from healthy female controls (n = 11), attenuated patients (n = 5), revertants (n = 1), and classical FA subjects 
(n = 6). The percentage of skewing expression is quantified for each case, and median values are indicated by horizontal bars. The threshold for 
skewed unbalanced expression was arbitrarily fixed (dashed horizontal line). Each symbol represents a patient.
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FANCD2-silenced HeLa cell line as an FA-like cell line for its conve-
nience with cotransfection. G2 arrest was abrogated in CHK1- and 
ATR-depleted cells; in contrast, ATM, CHK2, and BRCA1 depletion 
did not affect G2 arrest (Figure 4A). We then evaluated the effect of 
checkpoint inhibitors on FA lymphoblastoid (EBV-immortalized) 
cells. An inhibitor of CHK1, but not CHK2, relieved the G2 arrest 
(Figure 4B). Similarly, fresh FA PBLs were converted to attenuated 
cells by the CHK1 inhibitor (Supplemental Figure 4).
We next examined whether CHK1 inhibition protected FA cells 
from MMC-induced cell death in short-term cultures. FA primary 
fibroblasts were grown with or without CHK1 inhibitor in increas-
ing concentrations of MMC. Cell death was reflected by the nascent 
fraction of cellular fragments (sub-G1) by flow cytometry. Strikingly, 
FA cells that were incubated with the CHK1 inhibitor were protected 
from MMC-induced death (Figure 5 and Supplemental Figure 5).
These data demonstrate that inhibition of CHK1 or ATR, but 
not CHK2, ATM, or BRCA1, mimics the attenuated phenotype in 
FA cells. The absence of CHK1 abrogates the G2 checkpoint and 
protects FA cells from death, consistent with our hypothesis that 
clonal attenuation in FA improves survival.
Attenuated phenotype in FA patients with MDS with excess blasts or 
acute leukemia. Five out of the ninety-seven FA patients had MDS 
with an excess of blasts or overt myeloid leukemia. In all of these 
patients, aged 16, 20, 26, 36 and 50 years, the PHA-stimulated 
PBLs had the attenuated phenotype (i.e., chromosome breaks and 
no FANCD2 monoubiquitination but no G2 arrest). This finding 
raises the possibility that the attenuated phenotype is involved in 
malignant transformation. We could purify blast cells from fresh 
bone marrow aspirate in 4 out of the 5 patients and measured 
CHK1 and CHK2 expression. The clonal origin and purity of the 
CD34-sorted cells were confirmed by array-CGH (data not shown). 
Importantly, the tumoral cells expressed minute levels of CHK1 
but not of CHK2 (Figure 6), reminiscent of what was observed in 
attenuated PBLs, suggesting that leukemic cells would be unable 
to arrest through the ATR-CHK1 axis. In line with published data 
(32), very low levels of CHK1 were also found in a reference series 
of primary AML cells from non-FA patients (Figure 6), consistent 
with a model of suppression of the DNA damage response in AML 
as a late transformation event (Figure 7). Importantly, chemo-
therapy treatment (33) effected complete remission in these FA 
patients with MDS/AML, demonstrating that the leukemic cells 
were sensitive to chemotherapy.
Discussion
Based on our analysis of patients who were evaluated in a spe-
cialist center, we identified a type of spontaneous evolution in 
FA — attenuation, an acquired abrogation of the G2 checkpoint 
in FA cells (Figure 1). FA patients with the attenuated pheno-
type were older than classical FA subjects and had near-normal 
blood cell counts, suggesting that this phenotype is beneficial 
for hematopoiesis. Therefore, our working hypothesis has been 
that checkpoint attenuation allows FA cells to survive despite 
Figure 3
Low expression of CHK1 and p53, but not CHK2, in attenuated FA patients. (A) Immunoblot analysis of PHA-stimulated PBL extracts from an 
attenuated FA patient, 2 classical FA subjects, and a healthy donor, with increasing concentrations of MMC. (B) CHK1 and CHK2 levels were quan-
tified by RQ-PCR in PHA-stimulated PBLs of classical FA patients (n = 11), attenuated FA patients (n = 8), and healthy donors (n = 3). RQ-PCR 
copy number values are expressed using the ΔCT method relative to a housekeeping gene (reverse log2 scale). Mean values are indicated by 
horizontal bars. Statistical analyses were performed using the non-parametric Wilcoxon test (*P < 0.05). Each symbol represents a patient. (C) 
As shown in the left panel, proteasome inhibition partially restored CHK1 levels in the attenuated cells. Attenuated and control PHA-stimulated 
PBLs were incubated with the proteasome inhibitor MG132 or control DMSO for 4 hours. Then the level of CHK1 protein was analyzed by 
immunoblotting. As shown in the right panel, translational inhibition by CHX treatment revealed an increase of CHK1 decay in the attenuated 
PHA-stimulated PBLs compared with that in control PHA-stimulated PBLs. The CHK2 level was analyzed in parallel as a more stable protein.
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spontaneous DNA damage, whereas in classical (not attenu-
ated) FA cells, the DNA damage response pathway is deleteri-
ous by triggering unresolved checkpoint arrest. The distribution 
of the various phenotypes (classical, attenuated, and revertant) 
throughout different age groups suggests that a model exists 
in which hematopoiesis evolves clonally in most FA patients 
during adolescence or early adulthood as a response to stem 
cell exhaustion and selective pressure. Such evolution can arise 
spontaneously through attenuation or reversion, or it can be 
driven by allogeneic bone marrow transplantation. Attenuation 
Figure 4
Inhibition of CHK1 and ATR, but not CHK2, ATM, or BRCA1, mimics the attenuated phenotype in FA cells. (A) Cell cycle analysis of MMC-
induced G2 arrest in HeLa cells transfected with combinations of siRNAs (si) against luciferase (control), FANCD2, and the checkpoint genes 
CHK1, CHK2, ATR, ATM, and BRCA1, as indicated. FANCD2-silenced HeLa cells displayed a strong MMC-induced G2 arrest and were used as 
FA-like cells for convenience in cotransfection experiments. The immunoblot shows the knockdown of different proteins for each siRNA. Arrows 
and asterisks indicate typical FA G2 arrest and its abrogation, respectively. All data were obtained in at least 3 independent experiments for each 
targeted gene with consistent results. (B) Abrogation of MMC-induced G2 arrest by the CHK1 inhibitor SB-218078 (CHK1i) but not by the CHK2 
inhibitor C3742 (CHK2i) in FA and non-FA EBV cells. DMSO was used as control, and all data were obtained in 3 independent experiments with 
consistent results. The arrows indicate the MMC-induced G2 arrest, and the asterisk designates the G2 checkpoint abrogation. Horizontal bars 
in A and B indicate the G1 and G2 cell cycle phases (M1 and M2, respectively). 
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could explain the pattern in families in which FA siblings have 
patent phenotypic differences despite similar genotypes, remi-
niscent of what has been observed for reversion. Notably, neither 
attenuation (this work), nor reversion (27) appears to protect 
against transformation into MDS and leukemia, and we believe 
that all FA patients have to be monitored for cancer detection 
for life, including, if possible, by a yearly bone marrow aspirate.
We investigated the biological mechanisms of attenuation by 
analyzing the prototypical checkpoint pathways in FA cells. CHK1 
levels, but not CHK2 levels, were frequently very low in attenuated 
blood cells. CHK1 downregulation was related to transcriptional 
and/or posttranslational mechanisms, and interestingly, miR15-
a, previously reported to silent CHK1 (30), could contribute to 
the low CHK1 levels. Downregulation of the ATR-CHK1 axis, 
but not ATM-CHK2 or BRCA1, by siRNA or chemical inhibitors 
abrogated the G2 arrest, mimicking the attenuated phenotype and 
confirming that CHK1 function is pivotal for G2 accumulation in 
FA cells (34–36). Moreover, CHK1 inhibition protected FA cells 
from DNA damage-induced immediate cell death, consistent with 
our model, in which G2 checkpoint attenuation allows FA cells to 
grow despite spontaneous DNA damage, in contrast to deleteri-
ous checkpoint responses in classical FA cells. In addition, CHK1 
downregulation is likely to contribute to the genetic instability 
through deregulation of the normal cell cycle transitions, espe-
cially G1/S and G2/M (refs. 37 and 38 and Supplemental Figure 
6). In genomic analyses of attenuated PBLs, we did not detect 
any mutation or focused deletion in CHK1 or TP53 but observed 
that these cells experienced frequent gross somatic chromosomal 
alterations, such as duplication of chromosome 1q (Supplemen-
tal Table 1). Notably, this chromosomal abnormality is common-
ly associated with clonal evolution in FA (39, 40), and it might be 
involved in the attenuation mechanism. It is noteworthy that the 
molecular target and related downstream pathways of gross chro-
mosomal abnormalities in neoplasias remain largely to be identi-
fied, see for instance trisomy 8 or monosomy 7 in clonal evolu-
tion of aplastic anemia or MDS/AML in non-FA patients (41–44). 
Finally, it is likely that other changes in pathways that regulate 
cellular stress, apoptosis, and senescence can also contribute to 
cell survival and transformation throughout the natural history 
of FA patients, as occurs in mice (45).
Genomic instability is a common feature of cancer, wherein it 
promotes the accumulation of genomic alterations, leading to 
the deregulation of oncogenes and tumor suppressor genes (46). 
In very rare genetic conditions, such as FA, the instability is con-
stitutive, and patients with this condition have a strong predispo-
sition to cancer (12–16). Recently, the DNA damage response has 
emerged as a major anticancer barrier, and DNA damage response 
inactivation is an important step for cancer progression (6–8). In 
our FA cohort, 5 patients with attenuated PBLs experienced MDS 
or AML. Strikingly, the leukemic cells expressed CHK2 but very 
low levels of CHK1, suggesting that these cells would fail to elicit 
CHK1-dependent checkpoint arrest. Therefore, the attenuation 
Figure 5
CHK1 inhibitor protects FA cells from DNA 
damage-induced cell death in short-term 
cultures. (A) Representative flow cytom-
etry–based analysis of cell death of FA 
primary fibroblasts, with or without CHK1i. 
The fraction of cellular fragments (sub-G1, 
bars) was measured in each condition. 
Consistent data were obtained in at least 
2 experiments for each of 4 unrelated FA 
patients. (B) Graphic representation of the 
percentage of cellular fragments measured 
in A. Annexin V staining is shown in Sup-
plemental Figure 5. (C) MGG staining of FA 
primary fibroblasts with or without CHK1i 
treatment with 25 ng/ml MMC (original 
magnification, ×160).
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phenomenon might contribute to leukemogenesis by promoting 
survival in an FA background of constitutive genomic instabil-
ity (Figure 7). In patients who do not have a genetic predisposi-
tion (non-FA patients), the common stepwise order of oncogenic 
events likely differs slightly (Figure 7). The genomic instability 
and induction of the DNA damage checkpoint are not constitu-
tive but are likely to be induced as a consequence of the initial 
oncogenic events (6–8), as in primary human MDS and AML 
(32, 44). As a result, the inactivation of DNA damage response 
pathways, often by TP53 inactivation, would allow cells to sur-
vive despite the persistent genomic instability, accelerating the 
progression to late stages (6–8, 32, 44, 47).
These findings and concepts have important implications, not only 
for gaining a better understanding of the clinical course of FA, but 
also for developing cancer treatments for FA and non-FA patients. 
Based on our data, the acquired attenuation of checkpoints gives a 
survival advantage to FA cells in a background of endogenous DNA 
damage. In contrast, one can predict that attenuated cancer cells will 
be highly sensitive to chemotherapy, unlike revertant cancer cells 
(27). In an environment of high and sustained DNA damage, such 
as that during chemotherapy, attenuated cells will die due to check-
point deficiencies and mitotic dysfunction. Accordingly, the 5 FA 
patients with MDS/AML and the attenuated phenotype who we eval-
uated responded very well to usual FA chemotherapy (33), and only 
1 experienced a relapse 7–42 months after treatment. Interestingly, 
these results and concepts in patients are consistent with a recent 
preclinical model in mice, in which concomitant abnormal levels of 
Atm, Chk2, and p53 are more sensitive to chemotherapy (48).
In conclusion, we believe that a care-
ful evaluation of hematopoietic attenu-
ation and reversion in FA patients can 
help understand and predict the clinical 
course of the disease. Further, in non-FA 
patients, the evaluation of genomic insta-
bility and checkpoint and repair pathways 
in cancer cells should also help clinicians 
tailor the chemotherapy and specifically 
target the relevant checkpoint/repair 
pathways (16, 49–53).
Methods
Patients and biological material collection and cell 
lines. This study was based on a cohort of FA 
patients, followed for 6 years at Saint-Louis 
Hospital, the French national reference center 
for FA. Written informed consent was obtained 
from the patients and/or their relatives. The 
study was approved by the Institutional Review 
Board at Hôpital Saint-Louis. Patients were aged 
1 to 56 years (median age, 12 years). All patients 
had an FA diagnosis based on classical FA tests, 
including the chromosomal breakage test (12, 
26). The FA-associated gene mutation data 
have been entered into the international IFAR 
registry (www.rockefeller.edu/fanconi/mutate); 
mutations data in the patients with the attenu-
ated phenotype are described in Supplemental 
Table 1. The 97 patients were distributed as fol-
lows: FA-A, n = 80; FA-G, n = 9; FA-D2, n = 7; 
other, n = 1, which is representative of all French 
FA patients. Patients were referred to using a unique identification number 
(EGF), following our nomenclature. Blood cells and primary fibroblasts were 
collected. CD34-positive cells from bone marrow of MDS/AML FA patients 
were purified using the CD34 MicroBead Kit (Miltenyi).
Several cell lines were EBV-derived from FA patients at our center and 
used for this study. The HeLa cell line that was used for functional studies 
was obtained from ATCC.
Cell culture and FA tests. Chromosomal breakage tests and FANCD2 
monoubiquitination analysis by immunoblot were performed on PBLs 
and fibroblasts using conventional methods (12, 26, 54).
For cell cycle analysis, MMC was used at 0, 30, and 75 ng/ml for PHA-
stimulated PBLs and at 0, 10, and 25 ng/ml for primary fibroblasts. In all 
experiments, growing cells (fresh PHA-stimulated PBLs or cultured pri-
mary fibroblasts) were treated with MMC, fixed in chilled 70% ethanol, 
washed with PBS after overnight storage at –20°C, and resuspended in 
propidium iodide in PBS with 0.1% Triton X-100 and 100 μg/ml DNase-
free RNase A. The stained cells were sorted on a Becton Dickinson FACS-
Calibur and analyzed using CellQuest (Becton Dickinson). Approximately 
10,000 cells per sample were analyzed. EBV and HeLa cells were treated 
with 0 and 75 ng/ml or 100 ng/ml MMC, respectively.
FA cell death after a 96-hour incubation with MMC, with or without 
CHK1 inhibitor, was calculated by measuring the percentage of cellular 
fragments (sub-G1), derived from a flow-based MMC-hypersensitivity test 
in primary fibroblasts (55). In parallel experiments, FA primary fibroblasts 
were grown in a Lab-tekII Chamber Slide (Nalge Nunc International) in 
increasing dilutions of MMC, with or without CHK1 inhibitor, and ana-
lyzed by in situ staining of adherent cells with May Grundwald Giemsa 
(MGG). Apoptosis was further analyzed by Annexin V staining.
Figure 6
Low expression of CHK1, but not CHK2, in the leukemic cells from MDS/AML FA patients (n = 4). 
Leukemic cells were purified by CD34+ selection; the clonality and high purity of the blast cell 
fraction was demonstrated in all of the 4 MDS/AML FA patients by array-CGH profiling, which 
detected chromosomal alterations (data not shown). Data from classical FA patient PHA-stimu-
lated PBLs are indicated as reference (several samples were reanalyzed with consistent results). 
Leukemic cells from a series of non-FA patients (n = 15) with AML were analyzed as malignant 
reference. RQ-PCR copy number values are expressed using the ΔCT method relative to a 
housekeeping gene (reverse log2 scale). Mean values are indicated by horizontal bars. Statistical 
analyses were performed using the non-parametric test Wilcoxon test (**P < 0.001). As expected 
from published data in MDS and AML in non-FA patients (32), very low levels of CHK1 transcripts 
were also found in the non-FA AML cells. Each symbol represents a patient.
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Chemical inhibitors. Chemical inhibitors against CHK1 (CHK1i; 
SB-218078 [Calbiochem]) and CHK2 (CHK2i; C3742 [Sigma-Aldrich]), 
were dissolved in DMSO and used at a final concentration of 1 μM and 
100 nM, respectively. The diluted solution of DMSO was used as control.
The translational inhibitor, cycloheximide (CHX; Calbiochem) and the 
proteasome inhibitor MG132 (Calbiochem) were dissolved in DMSO and 
used at a final concentration of 25 μg/ml and 20 μM, respectively. The 
diluted solution of DMSO was used as control.
Transfection. Targeted genes were knocked down by transient expression 
of siRNA against FANCD2 (5′-GGAGAUUGAUGGUCUACUAdTdT-3′), 
LUC (5′-CGUACGCGGAAUACUUCGAdTdT-3′), CHK1 (5′-GGACUU-
CUCUCCAGUAAACdTdT-3′), CHK2 (5′-GAACCUGAGGAGCCU-
ACCCdTdT-3′), ATR (5′-AACCUCCGUGAUGUUGCUUGAdTdT-3′), 
ATM (5′-AAGCGCCUGAUUCGAGAUCCUdTdT-3′), and BRCA1 
(5′-CUAGAAAUCUGUUGCUAUGdTdT-3′). All siRNA duplexes were 
purchased from Eurogentec, except CHK1, which was purchased from 
Dharmacon. siRNA or the combination of 2 different siRNAs were used 
at a final concentration of 100 nM. siRNA duplexes were transfected 
using the Lipofectamine Reagent (Invitrogen) according to the man-
ufacturer’s recommendations. Luciferase-specific siRNA served as the 
negative control. In all experiments, a fraction of transfected cells was 
analyzed by immunoblot to assess knockdown efficiency. For cell cycle 
experiments using transfected cells, HeLa cells were plated 24 hours 
before transfection, MMC was added 72 hours after transfection, and 
cells were harvested at 96 hours and immediately fixed.
Evaluation of clonality. Array-CGH (105K, Agilent Technologies) or SNP-
array (500K, Affymetrix) were used for genomic PBL DNA according to the 
manufacturer’s protocols. For SNP analysis, paired fibroblast DNA was 
used as a reference. Data were analyzed using DNA Analytics (Agilent Tech-
nologies) or Genomic Suite (Partek).
For X-linked inactivation analysis (56), 3 SNPs in X chromosome 
genes, subjected to X-linked inactivation, were studied: dbSNP 1126762 
(MPP1), dbSNP 9018 (FHL1), and dbSNP 1135363 (BTK). Primer 
sequences are shown in Supplemental Figure 7A. Briefly, SNPs were 
sequenced from genomic DNA of female FA patients to determine het-
erozygosity. The relative expression of each allele was determined by 
direct sequencing of PBL cDNA. Balanced or skewed ratios were deter-
mined by direct evaluation of the chromatograms. Healthy females were 
evaluated as control.
Immunoblotting. Cell lysates were prepared in 50 mM Tris-HCl, 150 
mM NaCl, 0.1% SDS, and 1% NP-40 buffer. Antibodies were purchased 
against CHK1, CHK2, p53, ATM, CDC25A, actin (all from Santa Cruz 
Biotechnology Inc.), FANCD2 (Novus Biologicals), ATR (Cell Signal-
ing), BRCA1 (Calbiochem), and vinculin (Abcam). Signals were detected 
using an ECL kit (Pierce) and visualized with a Fuji LAS-3000 lumines-
cent image analyzer system.
CHK1 and CHK2 gene expression, miRNA expression. RNA samples, extract-
ed from PHA-stimulated PBLs were reverse transcribed, and the cDNA 
was analyzed for CHK1 and CHK2 expression by RQ-PCR using TaqMan 
methods (Applied Biosystems). Expression values were normalized to 
expression of the housekeeping gene GUS, using the ΔCT method, and 
are shown on a log2 scale.
After extraction of the dry pellet with the miRNeasy Kit, RT and 
RQ-PCR were performed with the miScript PCR System Kit (Qiagen), 
using specific primers to miR15-a and miR16-1. Data were normalized 
to RNU6b expression and represented in an arbitrary units, with a log2 
scale representation.
Genome-wide analysis of DNA methylation was performed by genomic 
methylated DNA immunoprecipitation, capture, and hybridization on 
Agilent Human CpG Island Microarrays as recommended by the supplier 
(Agilent Technologies).
Sequence analysis. The entire CHK1 open reading frame was sequenced 
on both strands. PCR was performed on 50 ng genomic DNA with Taq 
polymerase (Sigma-Aldrich), and the products were sequenced using the 
Figure 7
Genomic instability, DNA damage response, and stepwise oncogenesis — a model of stepwise progression to MDS/AML in patients with or 
without constitutive genetic instability. In FA patients, the first step is constitutive and leads to excess cell death related to the G2 checkpoint 
response; the attenuation phenomenon described here rescues cell survival and allows for the accumulation of additional oncogenic events that 
are favored by the genetic instability. In patients that are not genetically predisposed (non-FA patients), activation of oncogenes is associated 
with acquired genetic instability and induction of anticancer DNA damage response (6–8); further inactivation of this response, often by TP53 
inactivation, allows cancer progression to late stages (6–8, 32, 44, 47). Notably, no TP53 mutation or deletion was observed in the 5 MDS/AML 
leukemia cases that developed in attenuated FA patients in our series (data not shown).
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BigDye Terminator Cycle Sequencing Kit (Applied Biosystems). PCR 
primer sequences are listed in Supplemental Figure 7B. TP53 status was 
analyzed by direct DNA sequencing and functional analysis of separated 
alleles in yeast using the FASAY method as described previously (57).
Statistics. Statistical analyses were performed using the 2-tailed non-para-
metric Wilcoxon test. P values of less than 0.05 and less than 0.001 were 
considered as significant.
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